Risk of Technical Evaluation and Path Exploration of Social Governance——From the Investigation of Technical Evaluation of Medical Device
Yan Keshu1,2,Zhang Chenggang2,Wang Lanming3
1.China Food and Drug Administration Institute of Executive Development,Beijing 100073,China; 2.School of Social Science,Tsinghua University,Beijing 100084,China; 3.Department of Medical Device Registration,China Food and Drug Administration,Beijing 100053,China
Abstract：This paper,investigated empirically the risk in the technical evaluation of medical device.Governance theory is used to explore the path of social governance,mainly for the risk of the third parties’ failure.This paper also designed the system of the governance’s pattern,and provided policy recommendations:①The third party technical evaluation is an important way to break through the predicament of technical evaluation,but the government should be fully aware of the risk of third party technical evaluation,then explore its governance path and system construction;②The government should be in the core of the governance pattern to formulate relevant policies,establish the third party legal safeguard and supervise the behavior of the third parties;③The government should guide and promote the governance pattern of competition and cooperation,so that third party evaluation may get good development in the interaction with the government
鄢可书,张成岗,王兰明. 技术审评风险及社会治理路径探索——基于医疗器械技术审评的考察[J]. 中国科技论坛, 2016(8): 102-108.
Yan Keshu,Zhang Chenggang,Wang Lanming. Risk of Technical Evaluation and Path Exploration of Social Governance——From the Investigation of Technical Evaluation of Medical Device. , 2016(8): 102-108.
[1]程茂波,史新立,贾健雄.冠状动脉药物洗脱支架临床前研究的审评考虑[J].中国医疗器械杂志,2014,38(6):461-462. [2]MINHAA Sa’ar,WAKSMAN Ron.Evaluation of the Edwards lifesciences SAPIEN transcatheter heart valve[J].Expert review of medical devices,2014(8):553-562. [3]Anonymous.FDA medical device review path[J].The journal of nuclear medicine,2011,52(3):27N. [4]FRANK O Tyers.Medical device review in Canada[J].Pacing and clinical electrophysiology,1995,18(3):472-473. [5]JANET Newman.Modernising governance:new labour,policy and society[M].London:SAGA,2001. [6]国家药品监督管理局.关于印发《国家医疗器械审评专家库管理规定(试行)》的通知[EB/OL].(2003-01-29)[2015-07-28].http://www.sda.gov.cn/WS01/CL0059/9390.html [7]赵延东.风险社会与风险治理[J].中国科技论坛,2004(4):121-125. [8]张成岗.技术专家在风险社会中的角色及其限度.南京师大学报(社会科学版),2013,5(7):21-27. [9]BASSAK Gil.Tackling compliance reviews[N/OL].(2005-01-5)[2015-06-15].http://www.mdtmag.com/product-release/2005/01/tackling-compliance-reviews. [10]STEPHEN Barlas.Third-party review of medical device safety[J].Appliance,1997,54(9):24(1). [11]JONATHAN Kahan.Medical device third party review-will it work?[J].Clinica,1996,720(1):9(3). [12]CAMPBELL Noel D.Replace FDA regulation of medical devices with third-party certification[F/OL].(1997-11-12)[2016-01-14].Cato policy analysis,288 http://www.cato.org/pubs/pas/pa-288.html#FOOTNOTE_43 [13]SALAMON Lester M.Partners in public service:the scope and theory of government nonprofit relations[M]//POWEL W W.The nonprofit sector:a research handbook.New Haven:Yale University Press,1987. [14]European Commission.Proposal for a regulation of the european parliament and of the council on medical devices,and amending directive 2001/83/EC,regulation(EC)No 178/2002 and regulation(EC)No 1223/2009,2012/0266(COD)[EB/OL].(2012-09-26)[2015-07-09].http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2012:0542:FIN:EN:PDF [15]European Commission.Proposal for a regulation of the european parliament and of the council on in vitro diagnostic medical devices,2012/0267(COD)[EB/OL].(2012-09-26)[2015-07-09].http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2012:0541:FIN:EN:PDF [16]European Commission.Strengthening consumer safety:improving the safety of medical devices[EB/OL].(2013-09-24)[2015-07-15].http://europa.eu/rapid/press-release_IP-13-854_en.htm?locale=en [17]日本国厚生劳动省.关于以药事法为基准的行政处分[日][EB/OL].(2011-12-27)[2015-07-22].http://www.mhlw.go.jp/stf/houdou/2r9852000001zbrz.html [18]日本国厚生劳动省.关于以药事法为基准的行政处分[日][EB/OL].(2013-03-18)[2015-07-22].http://www.mhlw.go.jp/stf/houdou/2r9852000002xepa.html [19]俞可平.治理与善治[M].北京:社会科学文献出版社,2003. [20]埃莉诺·奥斯特罗姆.公共事物的治理之道[M].上海:上海三联书店,2000. [21]JESSOP Bob.The future of the capitalist state[M].Cambridge:Polity Press,2002:242-243. [22]WHITEHEAD Mark.In the shadow of hierarchy:meta-governance,policy reform and urban regeneration in the West Midlands[J].Area,2003,35(1):6-14. [23]SRENSEN Eva,TORFING Jacob.Making governance networks effective and democratic through metagovernance[J].Public administration,2009,87(2):234-258. [24]王兰明.关于改革和完善中国医疗器械注册管理制度的探讨[J].中国医疗器械杂志,2012,36(6):426-432. [25]SALAMON Lester M.Partners in public service government-nonprofit relations in the modern welfare state[M].Johns Hopkins University Press,1995:19. [26]BRIGHT J.European medical device regulatory law and product liability[J].Journal of hospital infection(1999)43(Supplement):S169-S173 [27]董新宇,苏竣.科技全球治理下的政府行为研究[J].中国科技论坛,2003(6):79-82. [28]FDA center for devices and radiological health.implementation of third party programs under the FDA modernization act of 1997;final guidance for staff,industry and third parties[EB/OL].(2001-02-02)[2015-07-12].http://www.fda.gov/RegulatoryInformation/Guidances/ucm094450.htm
2016, 
